Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Keybanc Maintains Overweight on Watsco, Raises Price Target to $310

Keybanc Maintains Overweight on Watsco, Raises Price Target to $310

Keybanc analyst Jeffrey Hammond maintains Watsco (NYSE:WSO) with a Overweight and raises the price target from $300 to $310.

byBenzinga Newsdesk

September 6, 2022

1 minute read

Keybanc analyst Jeffrey Hammond maintains Watsco (NYSE:WSO) with a Overweight and raises the price target from $300 to $310.

Chardan Capital Maintains Buy on Homology Medicines, Lowers Price Target to $10

By Benzinga Newsdesk

August 16, 11:59 AM

Chardan Capital analyst Matthew Barcus maintains Homology Medicines (NASDAQ:FIXX) with a Buy and lowers the price target from $14 to $10.

FIXX

What’s Going On With Pinduoduo Stock Today?

By Adam Eckert

October 25, 3:48 PM

Pinduoduo Inc (NASDAQ: PDD) shares are trading higher Tuesday, rebounding after falling Monday amid news of Xi Jinping's third term.

PDD

Why Innovative Eyewear Shares Are Moving Higher

By Adam Eckert

June 20, 9:56 AM

Innovative Eyewear Inc (NASDAQ: LUCY) shares are trading higher Tuesday after the company announced a licensing agreement with Authentic Brands for

LUCY

Fortive: Q2 Earnings Insights

By Benzinga Insights

July 28, 8:11 AM

Fortive (NYSE:FTV) reported its Q2 earnings results on Thursday, July 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

FTV

Keybanc Maintains Overweight on Watsco, Raises Price Target to $310

Related Posts

Chardan Capital Maintains Buy on Homology Medicines, Lowers Price Target to $10

What’s Going On With Pinduoduo Stock Today?

Why Innovative Eyewear Shares Are Moving Higher

Fortive: Q2 Earnings Insights